The latest price target for Revance Therapeutics (NASDAQ:RVNC) was reported by Barclays on December 23, 2024. The analyst firm set a price target for $3.00 expecting RVNC to fall to within 12 months (a possible -8.81% downside). 24 analyst firms have reported ratings in the last year.

The latest analyst rating for Revance Therapeutics (NASDAQ:RVNC) was provided by Barclays, and Revance Therapeutics maintained their equal-weight rating.

The last upgrade for Revance Therapeutics Inc happened on August 16, 2023 when Exane BNP Paribas raised their price target to $20. Exane BNP Paribas previously had an underperform for Revance Therapeutics Inc.

The last downgrade for Revance Therapeutics Inc happened on September 13, 2024 when Barclays changed their price target from $10 to $7 for Revance Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Revance Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Revance Therapeutics was filed on December 23, 2024 so you should expect the next rating to be made available sometime around December 23, 2025.

While ratings are subjective and will change, the latest Revance Therapeutics (RVNC) rating was a maintained with a price target of $7.00 to $3.00. The current price Revance Therapeutics (RVNC) is trading at is $3.29, which is out of the analyst’s predicted range.